STK-012 + pembrolizumab + pemetrexed + carboplatin

STK-012 + pembrolizumab + pemetrexed + carboplatin is an investigational four-drug combination regimen. STK-012 is an early-stage drug candidate (details not fully published; presumed to be an immunotherapy or biologic)[comments]. Pembrolizumab is a monoclonal antibody against the programmed cell death protein 1 (PD-1), functioning as a checkpoint inhibitor[3][5][7]. Pemetrexed is an antineoplastic, antifolate cytotoxic chemotherapy; carboplatin is a platinum-based chemotherapy. This combination is being studied and used primarily as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC), leveraging immune checkpoint inhibition and cytotoxic chemotherapy for complementary anti-tumor effects[1][3][5][7].